{
    "10.1002/adhm.201800296.pdf": {
        "new materials": {
            "Yes/No": "Yes",
            "sentence": " The article mentions the development of ZnDPA-conjugated Fe"
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The paper does not mention any specific screening algorithms, but it discusses the development of an apoptosis-homing nanoplatform for tumor theranostics, which implies a method or approach to identify individuals with certain conditions or traits."
        },
        "AI algorithms": {
            "Yes/No": "Yes",
            "sentence": " The apoptosis-homing nanoplatform based on zinc(II) dipicolylamine (ZnDPA) conjugated Fe"
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": " The mice were divided into eight groups randomly.\n\nThe models mentioned in the article are:\n\n* Apoptotic I (4T1 tumor-bearing mice induced by DOX)\n* Apoptotic II (4T1 tumor-bearing mice induced by DOX twice for 3 d)\n* Normal group (4T1 tumor-bearing mice without treatment of DOX)\n\nThese groups are used to evaluate the amplifying apoptosis-targeted property of MNPs"
        },
        "funding": {
            "Yes/No": "No",
            "sentence": " There is no indication in this document that mentions who funded the research. The text only provides information about the study itself, its methods, and results, but does not include any information on funding sources or sponsors."
        },
        "material datasets": {
            "Yes/No": "No",
            "sentence": " The article does not mention sharing any AI or material-related datasets, as there is no mention of such sharing in the provided text."
        },
        "drug formulations explored": {
            "Yes/No": "No",
            "sentence": " The article has successfully developed ZnDPA-conjugated Fe@Fe3O4 NPs by strain-promoted click chemistry, which could be rendered as a nanotheranostic agent for enhanced photothermal therapy in vivo."
        },
        "novel drug formulations": {
            "Yes/No": "No",
            "sentence": " The article does not specifically identify any novel drug formulations, but rather reports on the development of ZnDPA-conjugated Fe@Fe3O4 NPs for enhancing MRI and photothermal therapy in cancer treatment."
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "No",
            "sentence": " According to the provided context, there is no mention of lead small-molecule drug candidates. The article primarily focuses on the development and characterization of Fe@Fe3O4 nanoparticles conjugated with ZnDPA for targeted photothermal therapy and imaging of apoptotic cancer cells."
        },
        "clinical trials": {
            "Yes/No": "No",
            "sentence": " There is no mention of clinical trials in the article; it appears to be a research study focused on developing and evaluating an apoptosis-homing nanoplatform for tumor theranostics."
        }
    },
    "10.1002_adhm.201800296.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " The MNP"
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " This nanoplatform provides a promising strategy to improve the targeting efficiency of nanoparticles and the enhancement of tumor-targeting theranostics."
        },
        "experimental methodology": {
            "Yes/No": "**Novel experimental methodology:** Yes",
            "sentence": " The amplifying apoptosis-targeted T2-weighted MR imaging in vivo of MNPs"
        },
        "ML algorithms": {
            "Yes/No": "No",
            "sentence": " The tumor-homing ability of nanomaterials plays a key role in achieving their cancer precision theranostics."
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": " The tumor-homing ability of nanomaterials plays a key role in achieving their cancer precision theranostics."
        },
        "funding": {
            "Yes/No": "Yes",
            "sentence": " The authors acknowledge the financial support of the National Natural Science Foundation of China (Grant Nos. 81671862 and 81972297)."
        },
        "material datasets": {
            "Yes/No": "No",
            "sentence": " The amplifying apoptosis-targeted T- weighted MR imaging in vivo of MNPs"
        },
        "drug formulations explored": {
            "Yes/No": "Yes",
            "sentence": " Notably, they can be incorporated in pharmaceutical formulations to enhance drug solubility, absorption, and bioavailability due to the formulation itself and the P-gp inhibitory effects of the excipients."
        },
        "novel drug formulations": {
            "Yes/No": "Yes",
            "sentence": " The amplifying apoptosis-targeted T-weighted MR imaging in vivo of MNPs"
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "Yes",
            "sentence": " The degree of apoptosis on the different tumor models was further confirmed by fluorescent TUNEL staining (Figure S7, Supporting Information)."
        },
        "clinical trials": {
            "Yes/No": "No",
            "sentence": " The lack of information on current or future clinical trials involving MNPs"
        }
    },
    "10.1007_s12598-020-01402-8.pdf": {
        "new materials": {
            "Yes/No": "Yes",
            "sentence": " The emphasis of the new Rec.2020 ultra-high-definition television (UHDTV) standard is not on resolution but on color reproduction, which relies on the following primary colors: 630 nm for red, 532 nm for green, and 467 nm for blue..."
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The authors \"investigated the oxidation pathway of Sn-based perovskite film and determined that the formation of SnI was the crucial step.\""
        },
        "experimental methodology": {
            "Yes/No": "The document mentions introducing HPA (Hydrogen Phosphate) as a viable solution to the oxidation issues of Sn-based perovskite, which is a novel experimental methodology.\n\nYes",
            "sentence": " The authors investigated the oxidation pathway of Sn-based perovskite film and determined that the formation of SnI was the crucial step. With this knowledge, preventing the formation of SnI was proposed as an effective solution."
        },
        "ML algorithms": {
            "Yes/No": "No",
            "sentence": " The authors also evaluated the color stability under changing temperatures, power and applied potential, finding that the emission shift was<3 nm at low temperature and high power, and less than 0.3 nm V-1 at working voltage (Fig. 1c). \n\n(There is no mention of any new machine learning or deep learning algorithm development in this document)"
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": " The authors introduced HPA (hydrogen phosphoric acid) as a viable solution to the oxidation issues of Sn-based perovskite and opens a pathway for future developments of Sn-based perovskite devices with even higher performance."
        },
        "funding": {
            "Yes/No": "Yes",
            "sentence": " The emphasis of the new Rec.2020 ultra-high-definition television (UHDTV) standard is not on resolution but on color reproduction, and this work was supported in part by RareMet. https:"
        },
        "material datasets": {
            "Yes/No": "No",
            "sentence": " Overall, the report by Liang and coworkers demonstrates a promising candidate for UHDTVs."
        },
        "drug formulations explored": {
            "Yes/No": "No",
            "sentence": " To avoid oxidation, the authors investigated the oxidation pathway of Sn-based perovskite film and determined that the formation of SnI was the crucial step."
        },
        "novel drug formulations": {
            "Yes/No": "No",
            "sentence": " The authors report that H PO (HPA) was introduced into Sn precursors as a mild reducing agent with good coordinating ability, which not only impedes the oxidation through inhibiting SnI formation but also improves film quality via seeding the crystal growth."
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "No",
            "sentence": " The authors chose the Sn-based perovskites with natural quantum well structure as active layers for light emission."
        },
        "clinical trials": {
            "Yes/No": "No",
            "sentence": " The authors evaluated the color stability under changing temperatures, power and applied potential, finding that the emission shift was\\3 nm at low temperature and high power, and less than 0.3 nm(cid:2)V-1 at working voltage (Fig. 1c)."
        }
    },
    "10.1039_c8sc04808h.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " The unexpected presence of Ni(II)-thienyl iodide after polymerizing XMg-Th-Cl or XMg-Th-Br (I"
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The KCTP catalytic cycle involves four steps: transmetalation (TM), reductive elimination (RE), ring walking (RW) and oxidative addition (OA)."
        },
        "experimental methodology": {
            "Yes/No": "The document mentions a \"novel trend\" in the catalytic cycle (Fig. 4) and \"new insights into the polymerization mechanism\" (Fig. S9, ESI\u2020), but it does not explicitly mention any novel experimental methodology used.\n\nAs for screening algorithms, the answer is:\n\nNo",
            "sentence": " There are no sentences mentioning screening algorithms in the document."
        },
        "ML algorithms": {
            "Yes/No": "Yes",
            "sentence": " The authors conclude that the catalyst rests mostly as Ni(II)-thienyl iodide complex 1 in the polymerization of XMg-Th-I based on its stronger NMR signals."
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": "We developed a novel synthesis method for hydrothermal reactions under a phosphoric acid medium and obtained a series of metal polyiodates with strong SHG effects."
        },
        "funding": {
            "Yes/No": "Yes",
            "sentence": " This journalis \u00a9 The Royal Society of Chemistry 2018."
        },
        "material datasets": {
            "Yes/No": "Yes",
            "sentence": " The unexpected presence of Ni(II)-thienyl iodide after poly-merizing XMg-Th-Cl or XMg-Th-Br (I"
        },
        "drug formulations explored": {
            "Yes/No": "No",
            "sentence": " The catalyst rests as dissociated Ni(phosphine) complex and Ni(II)-dithienylcomplex2isobserved,howeveranadditionaldistinctandsharp singlet appears around 50 ppm."
        },
        "novel drug formulations": {
            "Yes/No": "Yes",
            "sentence": " The polymerization of XMg-Th-I, but we find that there is an additional distinct and sharp singlet around 50 ppm, which is indicative of phosphorus nuclei in an identical chemical environment."
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "Yes",
            "sentence": " In polymer chemistry, cross coupling reactions are particularly important for the synthesis of p-conjugated polymers."
        },
        "clinical trials": {
            "Yes/No": "Yes",
            "sentence": " The percent buried volume (%V) around the Ni centre in complex 2 calculated by DFT increases moving from Cl to Br to I."
        }
    },
    "10.1016_j.conbuildmat.2018.03.223.pdf": {
        "new materials": {
            "Yes/No": "Yes",
            "sentence": " The major components of PC include lime (CaO), alumina (Al2O3), ferrite (Fe2O3), and quartz, while r-MgO consists of MgO and some minor quantities of quartz and anhydrite, as indicated in Fig. 1."
        },
        "screening algorithms": {
            "Yes/No": "Yes",
            "sentence": " The document does not explicitly mention new high-throughput screening algorithms, but it discusses using \"RCPT\" and \"micro-tensile test\"."
        },
        "experimental methodology": {
            "Yes/No": "Based on the provided text, here are the answers to the questions:\n\n1. Does the document mention any new or novel experimental methodology used?\n\nYes",
            "sentence": " The current study investigated the effect of different w"
        },
        "ML algorithms": {
            "Yes/No": "No",
            "sentence": " The document does not mention the development of any new machine learning and deep learning algorithm or AI model"
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": " The principle of this method is based on the precipitation of whitish silver chloride, when silver nitrate is sprayed on Cl-penetrated areas, and brownish silver oxide precipitation, when silver nitrate is sprayed on OH(-) rich areas."
        },
        "funding": {
            "Yes/No": "No",
            "sentence": " This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC), grant number RGPIN-2015-04351."
        },
        "material datasets": {
            "Yes/No": "No",
            "sentence": " The same colorized area of the C50 concrete in Fig. 9(a) and (b) clearly illustrates this problem,"
        },
        "drug formulations explored": {
            "Yes/No": "Yes",
            "sentence": " The same colorized area of the C50 concrete in Fig. 9(a) and (b) clearly illustrates this problem."
        },
        "novel drug formulations": {
            "Yes/No": "Yes",
            "sentence": " Theprincipleofthismethodisbasedontheprecipitationofwhit- \nishsilverchloride,whensilvernitrateissprayedonCl-penetrated \nareas,andbrownishsilveroxideprecipitation,whensilvernitrate \nissprayedonOH(cid:4)richareas.Therefore,whitestripsoccuronone \nside of fractured surfaces of the A10, C10 and C30 concrete."
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "Yes",
            "sentence": " The use of this method has led to the development of r-MgO-PC concrete, which is shown to have an improved microstructure and strength compared to conventional Portland cement (PC) concrete."
        },
        "clinical trials": {
            "Yes/No": "No",
            "sentence": " None of the investigations mentioned involve human subjects, the document discusses concrete and its properties."
        }
    },
    "10.1002_qute.202000069.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " The statistics were computed using 100 data points sampled from the quantum generator with the optimized parameters after the training is completed."
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The document mentions a Quantum Generative Adversarial Network (QGAN), which is used to generate synthetic quantum states. However, it does not mention any new or novel high-throughput or large-scale screening algorithm, methods or workflow.\n\nNote: The QGAN is used in the context of generating synthetic quantum states for optimization and simulation purposes, but it is not a screening algorithm per se."
        },
        "experimental methodology": {
            "Yes/No": "Yes",
            "sentence": " We employ a Hybrid Quantum Generative Adversarial Network (HQGAN) that learns a classical target data distribution, with quantum circuits as discriminator and Neural Networks (NNs) as generator.\n\nThe screening algorithms used in the document are not explicitly mentioned. However, it can be inferred that the following algorithms were used:\n\n* Kullback\u2013Leibler divergence to measure the difference between the target and generated distributions\n* Objective functions (Cd and Cg) to evaluate the performance of the HQGAN\n* Norm of gradients (D grad and G grad) to monitor the convergence of the training process\n* Mean and standard deviation of the two distributions during training as a function of the number of epochs"
        },
        "ML algorithms": {
            "Yes/No": "Yes",
            "sentence": " The quantum machine learning community has shown a great interest in exploring the use of variational quantum circuits to boost the performance of the classical GANs, because of their inherent ease of sampling data from quantum distributions."
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": " The classicalGAN uses neural networks (NNs) as discriminator and generators, to learn the target data distribution, whereas a QGAN can be used in various scenarios-a fully quantum GAN with quantum circuits as discriminator and generator, for quantum data; hybrid quantum GAN with quantum circuit as discriminator and NNs as generator, for quantum or classical data."
        },
        "funding": {
            "Yes/No": "No",
            "sentence": " The authors acknowledge the use of Quil and PyTorch libraries for this work, but there is no mention of funding, award, or financial support."
        },
        "material datasets": {
            "Yes/No": "Yes",
            "sentence": " The noise models we use in our simulations include: 1) amplitude damping; 2) dephasing; 3) decoherence (a combination of amplitude damping and dephasing); and 4) a combination of amplitude damping, dephasing, and readout noise."
        },
        "drug formulations explored": {
            "Yes/No": "Yes",
            "sentence": " Notably, they can be incorporated in pharmaceutical formulations to enhance drug solubility, absorption, and bioavailability due to the formulation itself and the P-gp inhibitory effects of the excipients."
        },
        "novel drug formulations": {
            "Yes/No": "Yes",
            "sentence": " The objective of this study is to investigate if QGANs can be used for generative modeling in presence of noise, given the current state of the quantum resources."
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "Yes",
            "sentence": " The document does not mention identifying to developing lead small-molecule drug candidates, but it mentions an ideal generator circuit and simulations with ideal circuits for QGAN optimization."
        },
        "clinical trials": {
            "Yes/No": "No",
            "sentence": " The objective of this study is to investi-gate whether HQGANs can be used for generative modeling in the presence of noise, given the current state of the quantum resources."
        }
    },
    "10.1145_3386527.3405924.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " The research does not mention discovering new materials in this context, as it is focused on educational techniques and technologies."
        }
    },
    "10.1021_acsenergylett.0c02401.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " In this work, we sought to prevent salt formation by alternating our applied cell voltage between an operational voltage and a lower regeneration voltage."
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The document does not mention any new or novel high-throughput or large-scale screening algorithm, methods or workflow."
        }
    },
    "10.1016_j.drudis.2020.02.006.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " The putative druggable domains in the human genome were listed, but there is no mention of new or novel materials discovered."
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The document mentions various protein domains and their ligand desolvation values, but it does not mention any new or novel high-throughput or large-scale screening algorithm, methods, or workflow."
        },
        "experimental methodology": {
            "Yes/No": "The document does not mention any new or novel experimental methodology used.\n\nHowever, regarding the screening algorithms used in the document, the answer is:\n\nYes",
            "sentence": " Table 2 presents putative druggable domains in the human genome that were screened to identify potential targets for drug discovery.\n\nNote: The table mentions \"Putative druggable domains\" and \"ligand desolvation upon binding\", which suggests a computational approach was used to screen and identify these domains."
        },
        "ML algorithms": {
            "Yes/No": "Yes",
            "sentence": " The document mentions the use of AI, but it does not specifically mention the development of new machine learning and deep learning algorithm or AI model"
        },
        "models": {
            "Yes/No": "No",
            "sentence": " The SGC is a registered charity number 1097737 that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, and other sources."
        },
        "funding": {
            "Yes/No": "Yes",
            "sentence": " The SGC is a registered charity number 1097737 that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim."
        },
        "material datasets": {
            "Yes/No": "Yes",
            "sentence": " The document mentions the development of the \"DrugBank\" database, specifically in reference to its release version (CID: 143) and the update mentioned (CID: 2), but no new material-related datasets or databases are explicitly described."
        },
        "drug formulations explored": {
            "Yes/No": "No",
            "sentence": " The document does not mention exploring drug formulations, but rather lists \"putative druggable domains in the human genome\" and their characteristics."
        },
        "novel drug formulations": {
            "Yes/No": "No",
            "sentence": " The SGC is a registered charity number 1097737 that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Drug Discovery Today(cid:1)Volume 25, Number 3(cid:1)March 2020"
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "Yes",
            "sentence": " Table 2 Putative druggable domains in the human genomea Domain name Proteins in the human Median ligand desolvation with bound ligands in the PDB GPCR, rhodopsin-like 710 95 37 Protein kinase domain 482 90 195 WDR 266 77 4"
        },
        "clinical trials": {
            "Yes/No": "Yes",
            "sentence": " The human genome includes putative druggable domains with bound ligands in the PDB, which can be used to guide clinical trials."
        }
    },
    "10.1002_cmdc.202100018.pdf": {
        "new materials": {
            "Yes/No": "No",
            "sentence": " The title compound was prepared according to general procedure B using the aryl-indole 48(50mg,0.122mmol),"
        },
        "screening algorithms": {
            "Yes/No": "No",
            "sentence": " The document does not mention any new high-throughput or large-scale screening algorithm, methods, or workflow. The procedures and reactions mentioned in the document are standard organic synthesis protocols and do not involve novel screening algorithms or workflows."
        },
        "experimental methodology": {
            "Yes/No": "Based on the provided text, I can answer the questions as follows:\n\n1. Novel experimental methodology:\nThe document does not mention new or novel experimental methodology used.\n\n2. Screening algorithms:\nYes",
            "sentence": " A computer-assisted method was employed to screen and evaluate peptidomimetics, specifically a screening campaign using the Bcl-3 peptide library."
        },
        "ML algorithms": {
            "Yes/No": "No",
            "sentence": " The authors declare no conflict of interest."
        },
        "models": {
            "Yes/No": "Yes",
            "sentence": " This work was supported by a Natural Sciences and Engineering Research Council (NSERC) Discovery Grant (RB 2019-06368), and NSERC CREATE Grant (432008-2013). The SGC is a registered charity (no. 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU"
        },
        "funding": {
            "Yes/No": "Yes",
            "sentence": " The authors declare no conflict of interest."
        },
        "material datasets": {
            "Yes/No": "No",
            "sentence": " The title compound was prepared according to general procedure B using the aryl-indole 48 (50mg,0.122mmol), N-Boc-l-azetidine-2-carboxylic acid (25mg, 0.122mmol), PyBOP (63mg, 0.122mmol), DIPEA (0.16mL, 0.61mmol), and dry DMF (1.22mL)."
        },
        "drug formulations explored": {
            "Yes/No": "Yes",
            "sentence": " Preparation of compound 1 involved the addition of methyl iodide (0.58 mmol) to a solution of compound 7 (384.1386) and dry DMF (1.2 mL). Purification by RP-HPLC using a SiliCycle SiliaChrom dtC18 semipreparative column (5 \u03bcm, 100 \u00c5, 150 x 25 mm) was also mentioned in the document for compound 1."
        },
        "novel drug formulations": {
            "Yes/No": "Yes",
            "sentence": " The reactionmixturewasheatedto100\u00b0Candshakenfor24h.ThecrudemixturewasfilteredthroughapadofactivatedMPAluminaN(EcoChromTM)andwashedwithNMPandconcentratedundervacuum."
        },
        "lead small-molecule drug candidates": {
            "Yes/No": "Yes",
            "sentence": " General procedure E: Sulfone synthesis from thiophenol precur-sors. A stirred solution of substituted thiophenol (1equiv.), K 2CO 3 (1.4equiv.), and secondary bromoalkane (1.2equiv.) in dry acetone (0.3M), was stirred under nitrogen at reflux until completion of the reaction was observed by TLC (ca. 18h)."
        },
        "clinical trials": {
            "Yes/No": "No",
            "sentence": " There are no clinical trials mentioned in the document."
        }
    }
}